Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

• Status: Completed
• Trial end date: 2019-12-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of tobramycin inhalation solution (TIS) once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint is a reduction of exacerbations of the disease during the treatment period. Next to this parameter the investigators expect to show a significant beneficial effect on lung function parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Center Alkmaar
• Treatments: Pharmaceutical Solutions; Tobramycin

Criteria

Inclusion Criteria:

1. Age ≥ 18 years

2. The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of sputum

3. Confirmed non-CF bronchiectasis by (HR)CT

4. Documented history of at least 2 pulmonary exacerbations treated with courses of antibiotics within 12 months before inclusion.

5. No course of antibiotics or maintenance antibiotics (except for macrolides) 1 month prior to the start of the study.

6. Minimal one documented sputum or BAL-fluid culture with gram-negative bacteria or S.aureus within 12 months.

7. Growth of protocol defined pathogens in sputum at screening visit sensitive to tobramycin

8. Tolerance of inhaled tobramycin

Exclusion Criteria:

1. Any exacerbation within the month prior to the start of the study

2. Diagnosis of cystic fibrosis

3. Active allergic bronchopulmonary aspergillosis (ABPA)

4. Any oral, IV or inhaled antibiotics (except for macrolides) within 1 month prior to the start of the study

5. Any IV or IM corticosteroids or change in oral corticosteroids (> 10 mg) within 1 month prior to the start of the study

6. Any change/start treatment regimens macrolides, hypertonic saline, inhaled mannitol or other mucolytics, corticosteroids within 1 month prior to the start of the study

7. Change in physiotherapy technique or schedule within 1 month prior to the start of the study

8. Severe immunosuppression or active malignancy

9. Active tuberculosis

10. Chronic renal insufficiency (eGFR < 30 ml/min), use of loop diuretics

11. Have received an investigational drug or device within 1 month prior to the start of the study

12. Serious or active medical or psychiatric illness

13. Pregnancy and child bearing

14. History of poor cooperation or non-compliance

15. Unable to use nebulizers

16. Allergic for tobramycin